Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Michaelson

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2011
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancerM D Michaelson, J Bellmunt, G R Hudes, et al.
Biorxiv : the Preprint Server for Biology|March 31, 2025
The <i>Endo-GeneScreen</i> Platform Identifies Drug-Like Probes that Regulate Endogenous Protein Levels within Physiological ContextsPreston Samowitz, Laszlo Radnai, Thomas Vaissiere, et al.
Nature Communications|December 9, 2025
The Endo-GeneScreen platform identifies drug-like probes that regulate endogenous protein levels within physiological contextsPreston Samowitz, Laszlo Radnai, Thomas Vaissiere, et al.
British Journal of Cancer|May 15, 2014
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trialB Escudier, M D Michaelson, R J Motzer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2023
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinomaB A McGregor, G P Sonpavde, L Kwak, et al.
European Urology|January 14, 2017
Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital ExperienceNicholas J Giacalone, William U Shipley, Rebecca H Clayman, et al.
European Journal of Cancer (Oxford, England : 1990)|September 5, 2021
Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitorsHarish Seethapathy, Sarah Street, Ian Strohbehn, et al.
Kidney Cancer (Clifton, Va.)|October 19, 2018
Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path ForwardL C Harshman, C G Drake, N B Haas, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2011
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancerM D Michaelson, J Bellmunt, G R Hudes, et al.
Biorxiv : the Preprint Server for Biology|March 31, 2025
The <i>Endo-GeneScreen</i> Platform Identifies Drug-Like Probes that Regulate Endogenous Protein Levels within Physiological ContextsPreston Samowitz, Laszlo Radnai, Thomas Vaissiere, et al.
Nature Communications|December 9, 2025
The Endo-GeneScreen platform identifies drug-like probes that regulate endogenous protein levels within physiological contextsPreston Samowitz, Laszlo Radnai, Thomas Vaissiere, et al.
British Journal of Cancer|May 15, 2014
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trialB Escudier, M D Michaelson, R J Motzer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2023
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinomaB A McGregor, G P Sonpavde, L Kwak, et al.
European Urology|January 14, 2017
Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital ExperienceNicholas J Giacalone, William U Shipley, Rebecca H Clayman, et al.
European Journal of Cancer (Oxford, England : 1990)|September 5, 2021
Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitorsHarish Seethapathy, Sarah Street, Ian Strohbehn, et al.
Kidney Cancer (Clifton, Va.)|October 19, 2018
Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path ForwardL C Harshman, C G Drake, N B Haas, et al.
Pageof 6